Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that its recombinant humanized anti-FXI bispecific antibody injection, LZSN2501, has been approved by China’s National Medical Products Administration (NMPA) to conduct clinical trials for the prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (IND) |
| Product | LZSN2501, recombinant humanized anti-FXI bispecific antibody injection |
| Classification | Category 1 therapeutic biologic |
| Indication | Prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA) |
| Announcement Date | 28 Oct 2026 |
| Developer | Joincare Pharmaceutical Group (SHA: 600380) |
Drug Profile & Mechanism of Action
- Molecule: LZSN2501, a Category 1 therapeutic biologic built on a dual-epitope bispecific antibody design targeting coagulation factor XI (FXI).
- Dual-Epitope Binding: Can simultaneously bind the A2 domain and the catalytic domain of FXI.
- Dual Mechanism: Exerts anticoagulant activity through two complementary actions — inhibiting FXI activation and blocking FXIa enzymatic activity.
- Therapeutic Rationale: FXI/FXIa pathway inhibition is a leading next-generation anticoagulation strategy, aiming to prevent thrombosis in high-risk orthopedic surgery settings while mitigating the bleeding risk associated with current mainstream anticoagulants.
Approved Trial Design – Phase I Study
| Parameter | Design |
|---|---|
| Trial Phase | Phase I |
| Design | Single-dose, dose-escalation study |
| Population | Healthy adult participants in China |
| Endpoints | Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles |
The NMPA-cleared study will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of LZSN2501 in healthy adult participants in China using a single-dose, dose-escalation design — the standard first-in-human approach for characterizing a novel biologic anticoagulant.
Market Impact & Outlook
- First-in-Human Step: The Phase I clearance moves LZSN2501 into clinical development, marking a milestone for Joincare’s innovative biologics pipeline in cardiovascular and thrombotic disease.
- Frontier Class Positioning: As a dual-epitope bispecific antibody against FXI, LZSN2501 joins an emerging global class of anticoagulants designed to decouple efficacy from bleeding risk — with TKA VTE prophylaxis as its initial target indication.
- Category 1 Status: Classification as a Category 1 therapeutic biologic reflects the product’s novelty under China’s regulatory framework for innovative drugs.
- Commercial Outlook: Trial timeline, enrollment plans, and subsequent development strategy beyond Phase I were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, safety, efficacy, and potential commercialization of LZSN2501. Actual results may differ materially due to risks including first-in-human safety and tolerability findings, pharmacokinetic and pharmacodynamic outcomes, subsequent regulatory review by the NMPA, and competitive dynamics in the anticoagulant market.-Fineline Info & Tech
